-
The once rare but very real risk of occupational HIV transmission continues to fade in the face of a host of prevention measures that include needle safety devices and post-exposure prophylaxis.
-
The Centers for Disease Control and Prevention is developing formal guidelines on preexposure prophylaxis (PrEP) to prevent HIV in men who have sex with men (MSM). In the interim, the CDC has issued the following recommendations to guide clinical practice.
-
For years HIV experts and advocates have warned that unless federal funding for the AIDS Drug Assistance Program (ADAP) was ramped up significantly then thousands of Americans could be left off the roles and face risks of illness and death without dependable access to antiretroviral therapy (ART).
-
In this issue: Apixaban and rivaroxaban near approval for nonvalvular atrial fibrillation; fidaxomicin for C. difficile infections; guideline for intensive insulin therapy; and FDA Actions.
-
At the 59th annual meeting of the american society of Tropical Medicine and Hygiene held in Atlanta, GA, Nov. 3-7, 2011, Dr. Paul Arguin, head of the Domestic Malaria Unit, presented Malaria Updates from the Centers for Disease Control and Prevention (CDC).
-
Routine lead screening of a 1-year-old u.s.-born son of Cambodian immigrants living in New York revealed an elevated blood lead level (10 mcg/dL).
-
Although undeniably useful, gram stains have become less accessible to physicians in an era when clinicians go to the laboratory infrequently to view specimens and hospital laboratories move off-site. This brief report describes a Honolulu hospital's approach to this problem.
-
On Oct. 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved updated recommendations for the use of quadrivalent (serogroup A, C, Y, and W-135) meningococcal conjugated vaccines (Menveo®, Novartis; and Menactra®, Sanofi Pasteur) for adolescents and persons with high risk for meningococcal disease.
-
The ECG above was obtained in the office from an older woman with hypertension and atypical chest discomfort. Has there been anterior infarction, or is this a "pseudo-infarct" pattern?
-
A new antidepressant that combines selective serotonin reuptake inhibition with partial agonism of the 5-HT1A receptor has been approved by the FDA. Vilazodone is marketed by Trovis Pharmaceuticals as Viibryd(TM).